Vestmark Advisory Solutions Inc. Raises Position in Eli Lilly and Company $LLY

Vestmark Advisory Solutions Inc. boosted its position in shares of Eli Lilly and Company (NYSE:LLY) by 33.5% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 17,545 shares of the company’s stock after buying an additional 4,400 shares during the period. Vestmark Advisory Solutions Inc.’s holdings in Eli Lilly and Company were worth $13,387,000 at the end of the most recent quarter.

Other hedge funds have also made changes to their positions in the company. Adapt Wealth Advisors LLC grew its holdings in shares of Eli Lilly and Company by 14.4% during the third quarter. Adapt Wealth Advisors LLC now owns 1,649 shares of the company’s stock worth $1,258,000 after buying an additional 207 shares in the last quarter. Princeton Capital Management LLC lifted its stake in shares of Eli Lilly and Company by 7.9% in the third quarter. Princeton Capital Management LLC now owns 16,350 shares of the company’s stock worth $12,475,000 after buying an additional 1,202 shares in the last quarter. Journey Advisory Group LLC lifted its stake in shares of Eli Lilly and Company by 1.0% in the third quarter. Journey Advisory Group LLC now owns 23,152 shares of the company’s stock worth $17,665,000 after buying an additional 234 shares in the last quarter. Rossby Financial LCC boosted its position in Eli Lilly and Company by 23.0% during the third quarter. Rossby Financial LCC now owns 1,523 shares of the company’s stock worth $1,257,000 after acquiring an additional 285 shares during the last quarter. Finally, Jackson Grant Investment Advisers Inc. grew its stake in Eli Lilly and Company by 0.9% during the 3rd quarter. Jackson Grant Investment Advisers Inc. now owns 2,811 shares of the company’s stock valued at $2,145,000 after acquiring an additional 24 shares in the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Trading Down 1.4%

NYSE LLY opened at $1,008.47 on Friday. The company has a debt-to-equity ratio of 1.54, a current ratio of 1.58 and a quick ratio of 1.19. The stock has a market capitalization of $951.35 billion, a P/E ratio of 43.94, a PEG ratio of 1.18 and a beta of 0.39. The firm’s 50-day moving average is $1,054.83 and its two-hundred day moving average is $916.64. Eli Lilly and Company has a 12 month low of $623.78 and a 12 month high of $1,133.95.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Wednesday, February 4th. The company reported $7.54 EPS for the quarter, topping the consensus estimate of $7.48 by $0.06. Eli Lilly and Company had a net margin of 31.66% and a return on equity of 102.94%. The firm had revenue of $19.29 billion for the quarter, compared to analyst estimates of $17.85 billion. During the same period in the prior year, the business posted $5.32 EPS. The business’s revenue for the quarter was up 42.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. On average, sell-side analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Friday, February 13th will be given a $1.73 dividend. The ex-dividend date of this dividend is Friday, February 13th. This represents a $6.92 annualized dividend and a yield of 0.7%. This is an increase from Eli Lilly and Company’s previous quarterly dividend of $1.50. Eli Lilly and Company’s dividend payout ratio is presently 30.15%.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on LLY shares. Truist Financial set a $1,281.00 target price on Eli Lilly and Company in a report on Thursday, February 5th. Barclays started coverage on Eli Lilly and Company in a research note on Thursday. They set an “overweight” rating and a $1,350.00 price objective on the stock. Jefferies Financial Group lifted their price target on Eli Lilly and Company from $976.00 to $1,300.00 and gave the stock a “buy” rating in a report on Thursday, January 8th. Daiwa Securities Group upped their price objective on shares of Eli Lilly and Company from $1,230.00 to $1,250.00 and gave the company a “buy” rating in a report on Wednesday. Finally, Sanford C. Bernstein restated an “outperform” rating on shares of Eli Lilly and Company in a research report on Friday, December 19th. Two research analysts have rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and five have given a Hold rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $1,228.54.

Key Stories Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Landmark long‑term Omvoh (mirikizumab) data — Phase 3 VIVID‑2 open‑label results showed >90% of Crohn’s patients who reached steroid‑free remission at one year remained steroid‑free at three years; low hospitalization and surgery rates reinforce Omvoh’s potential to reduce disease complications and extend market opportunity in IBD. Patients with Crohn’s disease maintained steroid-free remission for three years with Lilly’s Omvoh
• Positive Sentiment: Additional trial wins — Lilly reported another positive result for the Zepbound‑Taltz combination (psoriasis/obesity crossover strategy) and other pipeline progress that support revenue diversification beyond GLP‑1s. These clinical wins strengthen near‑ and medium‑term growth expectations. Lilly chalks up another trial win for Zepbound‑Taltz combo
• Positive Sentiment: Analyst support — Berenberg raised its price target from $950 to $1,050 while keeping a hold rating, signaling modest upside in analyst models that may buoy sentiment after recent gains. Berenberg adjusts price target on Eli Lilly
• Neutral Sentiment: Business development — Lilly entered a $100M licensing deal with CSL for clazakizumab, which diversifies partnerships and could add mid‑late‑stage value but is not immediately material to top‑line. Eli Lilly Enters $100 Million Licensing Agreement with CSL Limited
• Neutral Sentiment: New indications / trials — Lilly has launched/updated trials (e.g., brenipatide Phase 2 for opioid use disorder) that expand the pipeline but are early‑stage and carry typical clinical risk/reward. Eli Lilly pushes into opioid use disorder with new brenipatide Phase 2 trial
• Negative Sentiment: Valuation and GLP‑1 concentration risk — Commentary and analysis pieces flag that much of Lilly’s recent rally was driven by GLP‑1/weight‑loss momentum; competition and profitability normalization risks remain, which can prompt profit‑taking and cap further near‑term gains. Warning: This Skyrocketing Stock Has a Hidden Risk

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.